Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G. Richardson, Yen Charles, Jindriska Lindsay et al.|The Lancet Oncology|2019Cited by 383
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm studyJames R. Berenson, Regina A. Swift, Ralph V. Boccia et al.|British Journal of Haematology|2006Cited by 83
A Multicenter Phase II Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) for Patients with Relapsed or Refractory Multiple Myeloma.James R. Berenson, Sal Bevivino, Ralph V. Boccia et al.|Blood|2005Cited by 5